UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 16, 2016
Karyopharm Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36167 | 26-3931704 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 85 Wells Avenue, 2nd Floor Newton, MA |
02459 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (617) 658-0600
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
Karyopharm Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders on June 16, 2016. The following is a summary of the matters voted on at that meeting.
| 1. | The Company’s stockholders elected Garen G. Bohlin, Mikael Dolsten, M.D., Ph.D. and Michael G. Kauffman, M.D., Ph.D. as class III directors to serve until the 2019 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such class III directors were as follows: |
| Votes For | Votes Withheld | Broker Non-Votes | ||||||||||
| Garen G. Bohlin |
25,233,364 | 285,195 | 5,142,363 | |||||||||
| Mikael Dolsten, M.D., Ph.D. |
25,492,384 | 26,175 | 5,142,363 | |||||||||
| Michael G. Kauffman, M.D., Ph.D. |
25,502,284 | 16,275 | 5,142,363 | |||||||||
| 2. | The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the current fiscal year. The results of the stockholders’ vote with respect to such ratification were as follows: |
| Votes For |
Votes Against |
Votes Abstaining |
Broker Non-Votes | |||
| 30,597,320 |
62,502 | 1,100 | 0 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KARYOPHARM THERAPEUTICS INC. | ||||||
| Date: June 17, 2016 | By: | /s/ Christopher B. Primiano | ||||
| Christopher B. Primiano | ||||||
| Senior Vice President, Corporate Development, General Counsel and Secretary | ||||||